JPWO2020219668A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020219668A5 JPWO2020219668A5 JP2021562908A JP2021562908A JPWO2020219668A5 JP WO2020219668 A5 JPWO2020219668 A5 JP WO2020219668A5 JP 2021562908 A JP2021562908 A JP 2021562908A JP 2021562908 A JP2021562908 A JP 2021562908A JP WO2020219668 A5 JPWO2020219668 A5 JP WO2020219668A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- pharmaceutical composition
- txnrd1
- subject
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025081069A JP2025127483A (ja) | 2019-04-24 | 2025-05-14 | Ｒａｓ変異体癌を治療するための組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962838065P | 2019-04-24 | 2019-04-24 | |
| US62/838,065 | 2019-04-24 | ||
| PCT/US2020/029513 WO2020219668A1 (en) | 2019-04-24 | 2020-04-23 | Compositions and methods for treating ras-mutant cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025081069A Division JP2025127483A (ja) | 2019-04-24 | 2025-05-14 | Ｒａｓ変異体癌を治療するための組成物および方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022529824A JP2022529824A (ja) | 2022-06-24 |
| JP2022529824A5 JP2022529824A5 (https=) | 2023-05-01 |
| JPWO2020219668A5 true JPWO2020219668A5 (https=) | 2023-05-01 |
| JP7770924B2 JP7770924B2 (ja) | 2025-11-17 |
Family
ID=72941253
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021562908A Active JP7770924B2 (ja) | 2019-04-24 | 2020-04-23 | Ｒａｓ変異体癌を治療するための組成物および方法 |
| JP2025081069A Pending JP2025127483A (ja) | 2019-04-24 | 2025-05-14 | Ｒａｓ変異体癌を治療するための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025081069A Pending JP2025127483A (ja) | 2019-04-24 | 2025-05-14 | Ｒａｓ変異体癌を治療するための組成物および方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220193109A1 (https=) |
| EP (1) | EP3959199A4 (https=) |
| JP (2) | JP7770924B2 (https=) |
| CN (1) | CN114025772A (https=) |
| WO (1) | WO2020219668A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4149941B1 (en) | 2020-05-15 | 2025-09-03 | Algen Biotechnologies, Inc. | Certain chemical compositions and methods of use thereof |
| CN113952359A (zh) * | 2021-11-19 | 2022-01-21 | 大连理工大学盘锦产业技术研究院 | 顺铂与Tri-1的联合抗肺癌药物组合物及其应用 |
| EP4551214A1 (fr) * | 2022-07-05 | 2025-05-14 | Association Française contre les Myopathies | Utilisation de l'ebselen ou l'un de ses derives pour traiter des pathologies ou dysfonctionnements des mitochondries |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2566519C (en) * | 2004-05-14 | 2020-04-21 | Rosetta Genomics Ltd. | Micrornas and uses thereof |
| CA2718400A1 (en) * | 2008-03-11 | 2009-09-17 | The General Hospital Corporation | Piperlongumine and piperlongumine analogs for use in the treatment of cancer |
| EP2954328A1 (en) * | 2013-02-05 | 2015-12-16 | Nestec S.A. | Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling |
| CN105263523A (zh) * | 2013-03-15 | 2016-01-20 | 米尔纳疗法公司 | 使用微rna和egfr-tki抑制剂的联合癌症治疗 |
| CA2958683A1 (en) * | 2014-09-10 | 2016-03-17 | The Regents Of The University Of California | Targeting k-ras-mediated signaling pathways and malignancy by prostratin |
| CN106687134A (zh) * | 2014-09-10 | 2017-05-17 | 加利福尼亚大学董事会 | 通过抗hLIF抗体靶向K‑RAS介导的信号转导通路和恶性肿瘤 |
| GB201514021D0 (en) * | 2015-08-07 | 2015-09-23 | Arner Elias Set Jeno | Novel Pyridines and their use in the treatment of cancer |
| WO2018145090A1 (en) * | 2017-02-06 | 2018-08-09 | New York University | Methods of treating cancers having a deregulated nrf2/keap1 pathway |
| EA201992781A1 (ru) * | 2017-05-22 | 2020-04-01 | Эмджен Инк. | Ингибиторы g12c kras и способы их применения |
| WO2018218087A1 (en) * | 2017-05-24 | 2018-11-29 | K-Gen, Inc. | Methods of cancer treatment |
| JP7377679B2 (ja) * | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法 |
-
2020
- 2020-04-23 EP EP20794527.0A patent/EP3959199A4/en active Pending
- 2020-04-23 CN CN202080045296.2A patent/CN114025772A/zh active Pending
- 2020-04-23 JP JP2021562908A patent/JP7770924B2/ja active Active
- 2020-04-23 WO PCT/US2020/029513 patent/WO2020219668A1/en not_active Ceased
- 2020-04-23 US US17/604,864 patent/US20220193109A1/en active Pending
-
2025
- 2025-05-14 JP JP2025081069A patent/JP2025127483A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019204938B2 (en) | Mdm2 inhibitors and combinations thereof | |
| US10238649B2 (en) | Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors | |
| Karampeazis et al. | Pemetrexed versus erlotinib in pretreated patients with advanced non–small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study | |
| JP7222895B2 (ja) | がんを治療するためのカボザンチニブとアテゾリズマブの組み合わせ | |
| Hudes et al. | NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy | |
| CN119947719A (zh) | 拉索昔芬联合治疗cdk4/6抑制剂治疗后进展的er+乳腺癌 | |
| Alruwaili et al. | A synergistic two-drug therapy specifically targets a DNA repair dysregulation that occurs in p53-deficient colorectal and pancreatic cancers | |
| Dy et al. | A front‐line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: North Central Cancer Treatment Group Study N0326 | |
| JPWO2020219668A5 (https=) | ||
| Harvey-Jones et al. | Systemic therapy for hereditary breast cancers | |
| Yoshida et al. | A randomized phase II study of maintenance bevacizumab, pemetrexed or bevacizumab plus pemetrexed for advanced non-squamous non-small cell lung cancer | |
| Quesada et al. | Perioperative FOLFOX in patients with locally advanced oesogastric adenocarcinoma | |
| Huang et al. | Synergistic antitumor activity of pro‐apoptotic agent PAC‐1 with cisplatinum by the activation of CASP3 in pulmonary adenocarcinoma cell line H1299 | |
| WO2015145388A2 (en) | Methods of treating colorectal cancers harboring upstream wnt pathway mutations | |
| US20200316067A1 (en) | Combination of raf inhibitors and taxanes | |
| CN102883720A (zh) | 治疗胰腺癌的方法 | |
| Noga et al. | Low incidence of neutropenic events in patients with lymphoma receiving first-cycle pegfilgrastim with chemotherapy: results from a prospective community-based study | |
| Pirasteh et al. | Utilizing the RAIN method and Graph SAGE Model to Identify Effective Drug Combinations for Gastric Neoplasm Treatment | |
| JP5881671B2 (ja) | チロシンキナーゼ型受容体ｋｉｔによって媒介される増殖性疾患のイマチニブによる処置を最適化する方法 | |
| JPWO2022178244A5 (https=) | ||
| Schittenhelm | What Does the Future Hold for the Treatment of FLT3-Mutated AML? News and Insights from ASH 2024 | |
| Urbini et al. | 2017P Comprehensive molecular profiling of small cell lung cancer patients treated with chemo-immunotherapy or chemotherapy alone | |
| HK40105136A (zh) | 治疗癌症的卡博替尼与阿特珠单抗组合 | |
| Srinivasa et al. | KDR gene as a Predictive Biomarker of Response to Regorafenib in Patients with Metastatic Colorectal Cancer (mCRC) | |
| Deng et al. | Tyrosine Kinase Inhibitors in the Elderly: A Case Report and Literature Review on Toxicity Profiles |